Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-10-02
2010-06-01
Fetterolf, Brandon J (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07727735
ABSTRACT:
An antigen is shown to be associated with prostate cancer, and is useful for new methods and compositions for diagnosing or treating prostate cancer. This is particularly useful for individuals with prostate cancer who test negative for Prostate Specific Antigen. Additionally, this is useful for distinguishing between benign prostate disease and prostate cancer in a patient diagnosed or presenting with prostate dysfunction.
REFERENCES:
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 5227160 (1993-07-01), Nudelman et al.
patent: 7135301 (2006-11-01), Magnani
patent: WO 97/03701 (1997-02-01), None
Nudelman et al. (The Journal of Biological Chemistry 1989; 264: 18719-18725).
Itai et al. (Cancer Research 1990; 50: 7603-7611).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Ballangrud et al., “Response of LNCaP Spheroids after Treatment with an α-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)1,”Cancer Research 61:2008-2014, 2001.
Saffran et al., “Target Antigens for Prostate Cancer Immunotherapy,”Cancer and Metastasis Review 18:437-449, 1999.
Bezosky and Berkower, “Immunogenicity and Antigen Structure,” inFundamental Immunology, 3rdEd., Chapter 8, Paul, W.E. (ed.), Raven Press, New York, NY, 1993, p. 242.
Itai et al., “Differentiation-dependent Expression of I and Sialyl I Antigens in the Developing Lung of Human Embryos and in Lung Cancers,”Cancer Res. 50:7603-7611, Dec. 1, 1990.
Kannagi et al, “Quantitative and Qualitative Characterization of Human Cancer-associated Serum Glycoprotein Antigens Expressing Fucosyl or Sialyl-Fucosyl Type 2 Chain Polylactosamine,”Cancer Res. 46:2619-2626, 1986.
Laganà, A. et al., “Determination of serum total lipid and freeN-acetylneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of freeN-acetylneuraminic acid as tumour marker,”Clinica Chimica Acta 243: 165-179, 1995.
Nudelman et al., “A Series of Disialogangliosides with Binary 2→3 Sialyllactosamine Structure, Defined by Monoclonal Antibody NUH2, Are Oncodevelopmentally Regulated Antigens,”J.Biol. Chem. 284(31): 18719-18725, Nov. 5, 1989.
Satoh, M. et al., “Glycolipid Expression in Prostatic Tissue and Analysis of the Antigen Recognized by Antiprostatic Monoclonal Antibody APG1,”Urol. Int. 48: 20-24, 1992.
Shiraishi, T. et al., “The glycosphingolipids of human prostate tissue,”Biochimica et Biohphysica Acta 961: 160-169, 1988.
Tsuji, Y. et al., “Human sperm carbohydrate antigens defined by an antisperm human monoclonal antibody derived from an infertile woman bearing antisperm antibodies in her serum,”Journal of Experimental Biology 168: 343-356, Jul. 1988.
Eccleston et al., “Pancreatic Tumour Marker Anti-Mucin Antibody CAM 17-1 Reacts with a Sialyl Blood Group Antigen, Probably I, Which Is Expressed Throughout the Human Gastrointestinal Tract,”Digestion 59:665-670, 1998.
Fetterolf Brandon J
GlycoMimetics, Inc.
Seed IP Law Group PLLC
LandOfFree
Detection and treatment of prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection and treatment of prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection and treatment of prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202225